Stocks Clock Fourth...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$1.50 0.00 | 0.00%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -37.32M | -20.96M | -19.18M | -30.24M |
| Operating Gains/Losses | 42.00K | 45.00K | -16.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | -195.00K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 55.00K | -574.00K | 391.00K | -817.00K |
| (Decrease) Increase In Other Current Liabilities | 941.00K | -259.00K | -2.18M | -1.71M |
| (Increase) Decrease In Other Working Capital | 0.00 | 174.00K | 4.00K | -1.00K |
| Other Non-Cash Items | 2.72M | -2.20M | -4.79M | 2.97M |
| Net Cash From Continuing Operations | -32.88M | -22.70M | -24.27M | -27.42M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -32.88M | -22.70M | -24.27M | -27.42M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 2.05M |
| Purchases of Property, Plant & Equipment | -636.00K | -106.00K | -101.00K | -147.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 200.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -636.00K | -106.00K | -101.00K | 2.10M |
| Issuance of Debt | 43.55M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 6.75M | 22.93M | 27.98M | 20.82M |
| Repayment of Long-Term Debt | -75.00K | -145.00K | -9.14M | -2.51M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 50.22M | 22.78M | 18.84M | 18.31M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 16.70M | -22.00K | -5.53M | -7.00M |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserKJP Spring Break
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Set to Explode 02.14.13 | 01:02 pm
- Discovery Labs Receives New US Patent For Pulmonary Surfactant Formulations 01.17.13 | 07:01 am
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Discovery Labs To Present At The Stifel Nicolaus Healthcare Conference 2012 09.04.12 | 07:09 am
- 8 Stocks Under $10 Surging Higher 08.28.12 | 02:08 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
Press Releases for DSCO
- Discovery Labs Announces Completion Of $14.25 Million Public Offering - PR Newswire 05.15.13 | 10:05 am
- Discovery Labs Prices $14.25 Million Public Offering Of Common Stock - PR Newswire 05.10.13 | 08:05 am
- Discovery Labs Announces Proposed Public Offering Of Common Stock - PR Newswire 05.09.13 | 04:05 pm
- Discovery Labs Announces Recent AFECTAIR® Publications - PR Newswire 05.01.13 | 07:05 am
- Discovery Labs Receives FDA Recommendations And Request For Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications - PR Newswire 04.15.13 | 07:04 am
- Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications - PR Newswire 03.29.13 | 07:03 am
- Discovery Labs To Report Fourth Quarter 2012 Results And Hold Conference Call On Wednesday, March 13, 2013 - PR Newswire 03.06.13 | 04:03 pm
- Discovery Labs Receives $30 Million Funding Commitment From Deerfield Management - PR Newswire 02.13.13 | 04:02 pm
- Discovery Labs Announces Changes To Board Of Directors And Appoints A New Chief Executive Officer - PR Newswire 01.04.13 | 08:01 am
- Discovery Labs Initiates Launch Of AFECTAIR® - PR Newswire 01.03.13 | 07:01 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
